

Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch

Diana N. Nunes^{a,1}, Emmanuel Dias-Neto^{a,b,1}, Marina Cardó-Vila^{c,d}, Julianna K. Edwards^e, Andrey S. Dobroff^{c,d}, Ricardo J. Giordano^f, Jami Mandelin^{e,2}, Helena P. Brentani^g, Catrin Hasselgren^{c,d}, Virginia J. Yao^{c,d}, Serena Marchiò^h, Carlos A. B. Pereiraⁱ, Fabio Passetti^j, George A. Calin^k, Richard L. Sidman^{l,4}, Wadih Arap^{c,m,3,4}, and Renata Pasqualini^{i,c,d,3,4}

^aLaboratory of Medical Genomics, A. C. Camargo Cancer Center, São Paulo 01509-010, Brazil; ^bLaboratory of Neurosciences, Institute of Psychiatry, University of São Paulo Medical School, São Paulo 05403, Brazil; ^cUniversity of New Mexico Cancer Center and Divisions of ^dMolecular Medicine and ^mHematology and Oncology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131; ^eGenitourinary Medical Oncology, David H. Koch Center and ^kDepartment of Experimental Therapeutics and Center for RNA Interference and Non-Coding RNAs, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; ^fDepartment of Biochemistry, ^lInstitute of Psychiatry, and ^hInstitute of Mathematics and Statistics, University of São Paulo, São Paulo 05508, Brazil; ^gLaboratory of Bioinformatics and Computational Biology, Division of Clinical and Translational Research, National Cancer Institute, Rio de Janeiro 20231, Brazil; ⁱCandiolo Cancer Institute–Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) and Department of Oncology, University of Turin, Candiolo, 10060, Italy; and ^hHarvard Medical School and Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02215

Contributed by Richard L. Sidman, January 14, 2015 (sent for review December 12, 2014)

Six members of the microRNA-17 (miR-17) family were mapped to three different chromosomes, although they share the same seed sequence and are predicted to target common genes, among which are those encoding hypoxia-inducible factor-1 α (HIF1A) and VEGFA. Here, we evaluated the *in vivo* expression profile of the miR-17 family in the murine retinopathy of prematurity (ROP) model, whereby Vegfa expression is highly enhanced at the early stage of retinal neovascularization, and we found simultaneous reduction of all miR-17 family members at this stage. Using gene reporter assays, we observed binding of these miRs to specific sites in the 3' UTRs of *Hif1a* and *Vegfa*. Furthermore, overexpression of these miRs decreased HIF1A and VEGFA expression *in vitro*. Our data indicate that this miR-17 family elicits a regulatory synergistic down-regulation of *Hif1a* and *Vegfa* expression in this biological model. We propose the existence of a coordinated regulatory network, in which diverse miRs are synchronously regulated to target the *Hif1a* transcription factor, which in turn, potentiates and reinforces the regulatory effects of the miRs on *Vegfa* to trigger and sustain a significant physiological response.

miRNA family | miRNA regulatory network | mouse neovascularization model | hypoxia | eye

MicroRNAs (miRs) are among the most important post-transcriptional regulators of gene expression and affect several normal biological processes, such as the cell cycle and cell fate determination during development, including angiogenesis. Recently, a large body of literature identified and confirmed a number of miRs that regulate angiogenesis (1–8).

In humans, the miR-17 family is composed of six distinct mature miRs located on three chromosomes: miR-17-5p and miR-20a are located on chromosome 13q31.3, miR-20b and miR-106a are located on chromosome Xq26.2, and miR-106b and miR-93 are located on chromosome 7q22.1. Members of this family seem to be derived from gene duplication events (9), and despite some divergences in length and nucleotide composition, their seed sequence (AAAGUG) is identical, an attribute suggestive of functional redundancy (10). Although the miR-17–92 cluster has been well-characterized, the regulatory role of the miR-17 family members has not been extensively studied (11, 12). Distinct prediction algorithms (13–16) indicate that the miR-17 miR family may target the 3' UTRs of genes encoding hypoxia-inducible factor-1 α (HIF1A) and VEGFA. Therefore, by simultaneously targeting these two key genes, miR-17 family members could, in theory, be important concerted regulators of angiogenesis. As proof of

concept, we tested this hypothesis in the experimental mouse model of retinopathy of prematurity (ROP), where *Vegfa* seems to be a pivotal factor that modulates the angiogenic switch (17–19). In this model, the expression of retinal *Vegfa* mRNA increases sharply 12 h after the animals are returned from 75% oxygen (O₂) back to room air (~21% O₂), a process that induces a relative hypoxic condition and leads to retinal neovascularization in the subsequent 9 d (17–19).

Here, we show the synchronous down-regulation of all members of the miR-17 family in the critical early steps of neovascularization in the ROP model. We propose an miR regulatory network, in which distinct and partially redundant miR-17 family members simultaneously affect the levels of the *Hif1a* transcription factor to posttranscriptionally (either directly and/or indirectly) increase the expression of one of its key downstream targets (i.e., *Vegfa*) (20–22), thereby influencing the physiological response to retinal hypoxia.

Significance

Retinal angiogenesis is a finely tuned biological phenomenon and a major cause of blindness. We studied the regulation of this phenomenon and identified cross-talk involving microRNAs (miRs) that share the same seed sequence, transcription factors, and angiogenesis effectors. In a mouse model of retinopathy of prematurity, we show the down-regulation of all miR-17 family members as an early event in the angiogenic switch, which resulted in increased levels of hypoxia-inducible factor-1 α and *Vegfa* *in vitro*. Notably, this coordinated regulation did not require the marked quantitative alterations of an individual miR but instead, relied on synchronous changes in members that share the same seed sequence. These results identify potential therapeutic targets in eye diseases with abnormal retinal angiogenesis.

Author contributions: D.N.N., E.D.-N., M.C.-V., J.K.E., A.S.D., R.J.G., and J.M. designed research; D.N.N., E.D.-N., M.C.-V., J.K.E., A.S.D., R.J.G., and J.M. performed research; H.P.B., C.A.B.P., F.P., G.A.C., and R.L.S. analyzed data; and D.N.N., E.D.-N., M.C.-V., C.H., V.J.Y., S.M., R.L.S., W.A., and R.P. wrote the paper.

The authors declare no conflict of interest.

Freely available online through the PNAS open access option.

¹D.N.N. and E.D.-N. contributed equally to this work.

²Department of Medicine, University of Helsinki, FI-00014, Helsinki, Finland.

³W.A. and R.P. contributed equally to this work.

⁴To whom correspondence may be addressed. Email: richard_sidman@hms.harvard.edu, warap@salud.unm.edu, or rpsqual@salud.unm.edu.




Fig. 2. Alignment of *HIF1A* and *VEGFA* genes shows highly conserved 3' UTRs. VISTA (visualization tool for alignment) alignments of human, mouse, and rat (A) *HIF1A* and (B) *VEGFA* genes show similar 3' UTRs together with TargetScan predictions of putative miR binding sites. miR target regions used for gene reporter assays are shown as black bars for both genes. (C) The strong conservation of the putative miR binding site in this region is shown in the detailed alignment of the miR-17-5p seed sequence to compare the 3' UTR from mammals, avians, and amphibians.

These results indicate that the miR-17 family members bind to the predicted 3' UTR region, and by doing so, they regulate the expression of both *Hif1a* and *Vegfa*.

miR-17 Family Members Regulate HIF1A and VEGFA Expression. To recapitulate in vitro the regulatory events observed in vivo, we used human Y79 retinoblastoma cells, which develop from immature retinas containing amacrine interneurons and Müller glial cells (28). Y79 cells express *VEGFA*, and Müller glial cells are especially active in the mouse neovascularization model (19). We observed reduced levels of *HIF1A* by ELISA (Fig. 4A) after transfecting cells with miR-20a ($P = 0.02$), miR-93 ($P = 0.01$), miR-106a ($P = 1.04 \times 10^{-5}$), and miR-106b ($P = 0.04$). Similarly, *VEGFA* levels decreased by 30% (ANOVA, $P < 0.05$) compared with baseline levels (Fig. 4B) after cell transfection with four of six family members [namely, miR-17-5p ($P = 0.02$), miR-20b ($P = 0.005$), miR-93 ($P = 0.02$), and miR-106b ($P = 0.001$)]. These results are consistent with our working hypothesis that *Hif1a* and *Vegfa* expressions are regulated by the miR-17 family during the early stages of the angiogenic switch in the ROP model.

Low Levels of miR-17 Family in the Initial Steps of the Angiogenic Switch. The discovery of miR regulation has added another dimension to the genetic study of cancer (29). This report corroborates this concept by extending the role of the miR-17 family to early angiogenic events, an important initial step in tumor progression. Because each miR can theoretically bind to and regulate hundreds of targets, one of the most intriguing questions concerns the translational regulation of the target genes (30). In the ROP model, we observed a consistent reduction of all six miR-17 family members and a corresponding increase in *Hif1a* and *Vegfa* protein levels within hours after mice pups were returned to room air after 5 d of high O_2 exposure. Conversely, the higher intracellular concentration of these miRs in transfected Y79 cells resulted in

a substantial reduction of *VEGFA* transcript and *HIF1A* and *VEGFA* protein expression. Theoretically, the effective trigger for angiogenesis—achieved after *HIF1A* and *VEGFA* up-regulation—would require simultaneous reduction of all of its negative regulators. Because these miRs share the same seed sequence, we expected—and observed—a similar response for each family member. Although a single miR is able to repress the production of hundreds of proteins, the cumulative effect may be relatively mild (31). In this case, finely tuned and complex biological processes, such as angiogenesis, require the concerted, simultaneous silencing of all miR-17 family members to bias the biological signals that ultimately lead to blood vessel formation.

In a previous study, Shen et al. (32) investigated miR alterations by microarray analysis using the ROP model. Shen et al. (32) evaluated a later time point (3 d after high O_2 exposure on day 15 vs. 6 and 12 h on day 12 as studied here), when the events that lead to *Hif1a* and *Vegfa* up-regulation have already occurred. Shen et al. (32) identified the levels of five miR-17 family members (miR-17-5p, miR-20a, miR-20b, miR-106a, and miR-106b) increased at this later time point. We also tested the expression levels of all miR members from the miR-17 family at this same time point using a more sensitive and specific approach (quantitative RT-PCR). In our hands, only miR-20b and miR-106b levels increased at this time point, whereas the expression levels of the other four members were down-regulated (data not shown).

It should be noted that the capability of some of the miR-17 family members to regulate *VEGF* and *HIF1A* expressions has been shown. For instance, the inhibition of miR-20b led to an incremental increase of *HIF1A* and *VEGF* protein levels in normoxic tumor cells, whereas the increase of miR-20b in hypoxic tumor cells decreased the levels of these two proangiogenic proteins (33). This study is the first demonstration, to our knowledge, of the simultaneous down-regulation of all miRs of the miR-17




Fig. 3. Regulation of *Hif1a* and *Vegfa* mRNAs by miR-17 family members. Gene reporter assays of (A) *Hif1a* or (B) *Vegfa* expression containing WT or mutated regions of the mouse 3' UTR show that members of the miR-17 family bind to specific 3' UTRs of these genes and regulate luciferase activity. Analyses were performed after 24 h of transfection using 10 nM each miR. miRNA, miR. Statistical significances are * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

family in the early time interval that precedes up-regulation of these important proangiogenesis factors.

We propose here that the simultaneous down-regulation of all miR-17 family members stimulates a positive cumulative effect on *Hif1a* and *Vegfa* expressions. When hypoxia supervenes after 5 d of high oxygen exposure, the induction of *Hif1a* expression seemed to increase by decreased levels of the miR-17 family. Lower levels of miR regulators would positively and simultaneously affect *Hif1a* and *Vegfa* protein levels. Higher *Hif1a* levels would certainly support higher *Vegfa* levels and probably contribute to drive the early steps of the angiogenic switch. These events could initiate a cascade that leads to consistent physiological responses without requiring additional quantitative alterations of miRs. This regulation scenario may not be exclusive to this miR family and these target genes. In this sense, Martinez et al. (34) describe a miR regulatory network in *Caenorhabditis elegans* of experimentally mapped interactions among transcription factors and miRs.

Angiogenesis is a multistep process that occurs over an extended period. As a tightly regulated physiological event, angiogenesis is a central biological phenomenon and a target for therapy in diseases, such as different forms of retinopathy and cancer, among other conditions. In this study, the importance of using an established, reproducible in vivo model was crucial to assess the complexity within an actual tissue microenvironment without the interference of artificial variables from an in vitro model. The reduction of all miR-17 family members simultaneously in the hypoxic retina as well as other tissues and tumors might be an early response to contextual signals within the tissue microenvironment that triggers neovascularization. In this context,

it is interesting to note that overexpression of some of the miRs evaluated here (namely miR-17 and miR-20a) inhibits metastasis (also an angiogenesis-dependent process) in pancreatic carcinoma cells (35) as well as breast cancer (36).

The physiologic response to hypoxia is complex. The manipulation of individual miRs in arbitrary concentrations and in vitro is unlikely to recreate this complex phenomenon. The hypoxia response and regulation of neovascularization by a limited set of miRs seem to be a short-duration, context-dependent process. As shown in Fig. 1E, all miRs evaluated in this study exhibited a significant decrease 12 h after the animals were returned to normoxia (ANOVA, $P < 0.01$). Of these miRs, miR-93 and miR-106a have been described as hypoxia-regulated miRs in cells exposed to hypoxic conditions (0.2% O_2) in vitro (7), but the miRs documented in this study showed an opposite trend in vivo. Although some studies showed that the levels of some of the miR-17 family members increase in solid tumors, others have shown deletion of genomic loci encoding these same miRs (37). In this cell context-dependent manner, Doebele et al. (38) show that overexpression of some members from the miR-17 cluster (miR-17; miR-18a, miR-19a, and miR-20a) leads to a decrease of endothelial cells sprouts in vitro. Conversely, in the same study, down-regulation of these miRs in vivo, particularly miR-17/miR-20, increases neovascularization but did not affect tumor angiogenesis. This observation is in accordance with our data and indicates that miR expression can, therefore, be expected to be specific in different cell types and physiological situations and thus, is context-dependent (39).




Fig. 4. miR-17 family members regulate HIF1A and VEGFA expression. Proteins derived from Y79 retinoblastoma cells transfected with each of the miR-17 RNAs show that each member of the miR-17 family decreased the levels of (A) HIF1A or (B) VEGFA expression as determined by ELISA. Analyses were performed after 24 h of transfection using 10 nM each miR. miRNA, miR. Statistical significances are indicated as * $P < 0.05$ and ** $P < 0.01$.

Another interesting analogous study showed significant down-regulation of miR-200b, an miR that targets *Vegfa*, in a mouse model of diabetic retinopathy (40). In this model, high blood glucose levels lead to down-regulation of miR-200 with subsequent up-regulation of *Vegfa* mRNA and *Vegfa* expression resulting in increased vascular permeability in vitro and in vivo.

This report puts forth a model in which the regulation of hypoxia-related genes by the miR-17 family occurs in tandem. Small reductions in the levels of miRs of all members of this family would lead to an incremental increase in Hif1a. Both higher Hif1a and lower miR levels subsequently trigger higher levels of *Vegfa* expression. This angiogenic cascade may have even broader effects, because some of these miRs have been shown to regulate *CTGF* and *TSP1* (both of which have proangiogenic properties) and are also predicted to target at least 14 additional angiogenesis-related genes (16) as well as another 5 genes recently predicted to be regulated by HIF1A (41, 42) (Fig. 5). Thus, it is conceivable that coordinated regulation of some of these genes by diminution of the miR-17 family levels might be an early step that leads to angiogenesis (Fig. 5). Within a larger context, it is interesting to note that hypoxia is also a well-known regulator of angiogenesis in cancer. Indeed, because poorly vascularized areas in solid tumors are hypoxic and low O₂ levels contribute to radiation therapy resistance (43), the miR regulation described here coupled with the hypoxic tumor microenvironment could trigger the angiogenic switch. This presumed key event occurs before blood vessel development to restore homeostasis and is required for solid tumor growth. Additionally, an even earlier event might be hypoxia-induced increase of p53 to suppress miR-17 elements at the transcriptional level by p53 binding to a specific site in the proximal region of the miR-17 promoter to competitively inhibit binding of a TATA binding protein transcription factor within an

overlapping site in the promoter region (44). Thus, a tantalizing role of the miR-17 family to regulate tumor angiogenesis remains an open question to be addressed in future studies.

In conclusion, we present three previously unrecognized findings. First, we show a decrease of all miR-17 family members in the in vivo ROP mouse model of angiogenesis. Second, we show that these miRs bind to the 3' UTRs of *Hif1a* and *Vegfa* and reduce the expression levels of these gene products after transfection into Y79 cells in vitro. Third, the miR-17 family members seem to be one of the earliest hypoxia-responsive molecular elements identified so far that triggers the angiogenic switch as part of an as yet unrecognized regulatory network of functional interactions.

Materials and Methods

ROP Model. Seven-day-old C57BL/6 pups and their mothers were kept in 75% O₂ for 5 d, after which the animals were transferred to room air and killed at 6 and 12 h thereafter (Fig. 1A). Experiments were performed in duplicate with two independent O₂ chambers. On average, five mice (i.e., 10 retinas) were used for each time point (0, 6, or 12 h) in each chamber as described (17–19). Retinas were immediately dissected under a stereomicroscope and kept in RNAlater (Ambion) at 4 °C until the RNA was extracted. Four animals from each chamber as well as four controls (i.e., not exposed to 75% O₂) were maintained until postnatal day 21 as negative controls for neovascularization. The Animal Care and Use Committee of the University of Texas M. D. Anderson Cancer Center approved all experiments (Animal Protocol 119909934). This study strictly adheres to the guidelines from the Association for Research in Vision and Ophthalmology statement.

RNA Extraction and Analysis. miRs and mRNAs were extracted using reagents from the mirVana miRNA Kit (Ambion). Selected miRs and mRNAs were quantified by real-time PCR with TaqMan microRNA Qsays (Applied Biosystems) or SybrGreen (sequences of primers and probes are available on request). snoRNA-202 and snoRNA-234 were used as endogenous controls for adjusting the expression of the miRs by real-time quantitative analysis. For mRNA quantification, the β -glucuronidase gene served as the endogenous control.

Gene Reporter Assays. The predicted 3' UTR target regions of both *Vegfa* and *HIF1A* genes, which contain the putative miR binding sites for miR-17 family members, were amplified by PCR, cloned downstream of the luciferase coding sequence in the pGL3 vector (Promega), and confirmed by DNA sequencing before transfection into COS-1 cells (4×10^4 cells per well in 96-microwell plates; ATCC). Plasmids containing mutated target regions were generated by deleting 7 nt in the miR binding sites using the QuikChange XL Site-Directed Mutagenesis Kit (Agilent Technologies). Plasmid constructs (100 ng per well) were cotransfected with *Renilla* luciferase pRL-CMV vector (2 ng per well) in the absence or presence of each miR-17 family member ($n = 6$) at a final concentration of 30 nM. Normalized luciferase ratios were determined 24 h after transfection using the Dual-Glo Luciferase Reporter-Assay System (Promega). All experiments were performed three times and contained 10 biological replicates each.

miR Transfections. Human Y79 retinoblastoma-derived cells (4×10^5 cells per well; ATCC) were transfected with Lipofectamine 2000 (Invitrogen) in 12-well plates with each of the six miRs from the miR-17 family. Distinct time points (3, 6, 12, and 24 h) as well as various miR concentrations (3, 10, and 30 nM) were tested to evaluate the effects of miR transfection on the levels of HIF1A and VEGFA expression relative to negative controls. Off-target effects and specificity of the selected miRs were further evaluated using the nontargeted, Cy5-labeled control 1 miR (Ambion) at the same time points and concentrations. Posttransfection levels of HIF1A and VEGFA expression were determined using an ELISA DuoSet Kit (R&D Systems). For HIF1A quantification, cells were lysed with RIPA buffer, and HIF1A levels were determined from 35 mg total resulting protein. Secreted VEGFA was determined from 15 mL Y79 cell-conditioned media. All experiments were repeated at least three times in triplicate.

Statistical Analysis. One-way ANOVA was used to assess the significance of the differences between groups. The criterion used for significance was $P < 0.05$.

ACKNOWLEDGMENTS. E.D.-N. is a research fellow from Conselho Nacional de Desenvolvimento Científico e Tecnológico and acknowledges the support received from Associação Beneficente Alzira Denise Hertzog Silva (to Laboratory of Neurosciences, University of São Paulo Medical School). This work was funded by National Institutes of Health Grant R01EY019459, and awards from the Gillson-Longenbaugh Foundation and the Marcus Foundation (to W.A. and R.P.).




Fig. 5. Working hypothesis schematic. miR-17 family members bind to and negatively regulate *Hif1a* expression, which also affects *Vegfa* expression and other proangiogenesis genes. These miRs also simultaneously down-regulate *Vegfa* expression, which directly affects angiogenesis. Because these miRs might also regulate other proangiogenesis genes, it is likely that fluctuations in miR levels would affect angiogenesis because of its action on many different targets.

1. Yang WJ, et al. (2005) Dicer is required for embryonic angiogenesis during mouse development. *J Biol Chem* 280(10):9330–9335.
2. Anand S, et al. (2010) MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. *Nat Med* 16(8):909–914.
3. Bonauer A, et al. (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. *Science* 324(5935):1710–1713.
4. Chen Y, Gorski DH (2008) Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. *Blood* 111(3):1217–1226.
5. Hua Z, et al. (2006) MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. *PLoS ONE* 1:e116.
6. Kuhnert F, et al. (2008) Attribution of vascular phenotypes of the murine *Egfl7* locus to the microRNA miR-126. *Development* 135(24):3989–3993.
7. Kulshreshtha R, et al. (2007) A microRNA signature of hypoxia. *Mol Cell Biol* 27(5):1859–1867.
8. Wang S, et al. (2008) The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. *Dev Cell* 15(2):261–271.
9. Tanzer A, Stadler PF (2004) Molecular evolution of a microRNA cluster. *J Mol Biol* 339(2):327–335.
10. Ventura A, et al. (2008) Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell* 132(5):875–886.
11. Olive V, Jiang L, He L (2010) miR-17-92, a cluster of miRNAs in the midst of the cancer network. *Int J Biochem Cell Biol* 42(8):1348–1354.
12. Mogilyansky E, Rigoutsos I (2013) The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. *Cell Death Differ* 20(12):1603–1614.
13. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: Targets and expression. *Nucleic Acids Res* 36(Database issue):D149–D153.
14. Krek A, et al. (2005) Combinatorial microRNA target predictions. *Nat Genet* 37(5):495–500.
15. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120(1):15–20.
16. Miranda KC, et al. (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. *Cell* 126(6):1203–1217.
17. Lahdenranta J, et al. (2001) An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration. *Proc Natl Acad Sci USA* 98(18):10368–10373.
18. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. *Proc Natl Acad Sci USA* 92(3):905–909.
19. Smith LE, et al. (1994) Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 35(1):101–111.
20. Guillemin K, Krasnow MA (1997) The hypoxic response: Huffing and HiFing. *Cell* 89(1):9–12.
21. Semenza GL (2007) Life with oxygen. *Science* 318(5847):62–64.
22. Arden GB, Sidman RL, Arap W, Schlingemann RO (2005) Spare the rod and spoil the eye. *Br J Ophthalmol* 89(6):764–769.
23. Camps C, et al. (2008) hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clin Cancer Res* 14(5):1340–1348.
24. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM (2009) MicroRNA regulation of DNA repair gene expression in hypoxic stress. *Cancer Res* 69(3):1221–1229.
25. Giannakakis A, et al. (2008) miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. *Cancer Biol Ther* 7(2):255–264.
26. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Ylä-Herttua S (2008) Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. *FEBS Lett* 582(16):2397–2401.
27. Würdinger T, et al. (2008) miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. *Cancer Cell* 14(5):382–393.
28. Famiglietti EV, et al. (2003) Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. *Brain Res* 969(1–2):195–204.
29. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. *Nat Rev Genet* 10(10):704–714.
30. Wilczynska A, Bushell M (2015) The complexity of miRNA-mediated repression. *Cell Death Differ* 22(1):22–33.
31. Baek D, et al. (2008) The impact of microRNAs on protein output. *Nature* 455(7209):64–71.
32. Shen J, et al. (2008) MicroRNAs regulate ocular neovascularization. *Mol Ther* 16(7):1208–1216.
33. Lei Z, et al. (2009) Regulation of HIF-1 α and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. *PLoS ONE* 4(10):e7629.
34. Martinez NJ, et al. (2008) A C. elegans genome-scale microRNA network contains composite feedback motifs with high flux capacity. *Genes Dev* 22(18):2535–2549.
35. Yan H, et al. (2010) MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. *Hum Gene Ther* 21(12):1723–1734.
36. Yu Z, et al. (2010) microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. *Proc Natl Acad Sci USA* 107(18):8231–8236.
37. Mendell JT (2008) miRiad roles for the miR-17-92 cluster in development and disease. *Cell* 133(2):217–222.
38. Doebele C, et al. (2010) Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. *Blood* 115(23):4944–4950.
39. Kuhnert F, Kuo CJ (2010) miR-17-92 angiogenesis micromanagement. *Blood* 115(23):4631–4633.
40. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S (2011) MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. *Diabetes* 60(4):1314–1323.
41. Benita Y, et al. (2009) An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. *Nucleic Acids Res* 37(14):4587–4602.
42. Dews M, et al. (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. *Nat Genet* 38(9):1060–1065.
43. Vaupel P, Harrison L (2004) Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. *Oncologist* 9(Suppl 5):4–9.
44. Yan HL, et al. (2009) Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. *EMBO J* 28(18):2719–2732.